Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Triheptanoin in McArdle Disease
NCT02432768Phase 2Completed
- Sponsor
- Rigshospitalet
- Start
- Apr 2015
- Primary completion
- Apr 2018
- Modality
- SLNs, Nanostructured Lipid Carriers, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Glycogen storage disease type 5 (GSD5) comparing Triheptanoin with Placebo oil (2 arms). Primary endpoint: Change in heart rate during constant load cycling exercise at Day 28. Started Apr 2015; status: completed.
02
Drugs
triheptanoin
03
Conditions
Glycogen storage disease type 5 (GSD5)
Beyond the preview
Go deeper on NCT02432768.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02432768.